معرفی
Professor Dan Siskind is an Adjunct Professor at the Queensland Brain Institute, The University of Queensland, and a clinical academic psychiatrist at Metro South Addiction and Mental Health Service. He holds an MBBS, MPH, PhD, and FRANZCP, with training in psychiatry across Australia and the United States. His research focuses on treatment-refractory schizophrenia, clozapine pharmacology, and physical health disparities in severe mental illness.
- University of Queensland (MBBS, PhD)
- Harvard University (MPH)
- Boston University (Psychiatry Residency)
His work addresses clozapine optimization, metabolic side effects of antipsychotics, and multimorbidity in mental health. He leads the MOVEMENT Study for exercise interventions and the COaST trial for semaglutide in clozapine-treated obesity. Recent articles emphasize digital health tools (SMART), myocarditis management, and transdisciplinary schizophrenia research.
He has received prestigious awards, including:
- NHMRC Investigator Grant (Emerging Leadership Fellow, 2021-2025)
- NHMRC Early Career Fellowship (2016-2019)
With over 240 peer-reviewed publications and AU$60M+ in research grants (AU$6.5M as CIA), he contributes to international schizophrenia guidelines (INTEGRATE) and co-develops interventions for smoking cessation and physical activity promotion in psychiatry settings.
